Autolus Therapeutics plc Operating Income

Quick Answer

Autolus Therapeutics plc reported Operating Income of -$270.54 million for fiscal year 2025.

Autolus Therapeutics plc Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$270.54M -12.1%
2024 -$241.43M -34.3%
2023 -$179.70M -25.3%
2022 -$143.41M -1.7%
2021 -$141.05M +16.1%
2020 -$168.15M -15.1%
2019 -$146.06M -153.9%
2018 -$57.53M -145.7%
2017 -$23.42M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$71.62M -5.5% -17.0%
June 30, 2025 -$61.22M -3.9% +6.2%
March 31, 2025 -$65.24M -68.3% +3.9%
September 30, 2024 -$67.88M -58.2% -15.2%
June 30, 2024 -$58.93M -32.8% -52.0%
March 31, 2024 -$38.76M +1.0% +9.7%
September 30, 2023 -$42.91M +1.4% +3.3%
June 30, 2023 -$44.38M -13.4%
  • Autolus Therapeutics plc showed a decrease of -12.1% in Operating Income compared to the prior fiscal year.
  • Over the 2017–2025 period, Autolus Therapeutics plc’s operating income has declined by 1055.3% (from -$23.42 million to -$270.54 million).
  • The most recent figure is from Autolus Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment